ALNY Phase 1 readout: a positive outcome, +7.1%

On June 1, 2025, ALN-APP — Alnylam Pharmaceuticals, Inc. (Alzheimer Disease) reached its Phase 1 readout. The result was a positive outcome, and the stock moved +7.1% in the window around the event. It had already run +12.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.